))
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Manage episode 414417317 series 3381434
Sisällön tarjoaa ReachMD. ReachMD tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
CME credits: 0.25
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/applying-sdm-to-personalize-treatment-discussions-on-recurrence-risk-reduction-in-patients-with-early-stage-melanoma/18105/
This Patient Clinician Connection CME activity, led by Dr. Meghan Mooradian, focuses on the use of adjuvant immunotherapy in early-stage melanoma. The activity aims to educate clinicians on the role of immunotherapy in reducing the risk of disease recurrence post-surgery, particularly in patients with resected stage IIB to III melanoma. Through patient clinical vignettes and audience education vignettes, participants will gain insights into patient-centered approaches, shared decision-making, and the management of immune-related adverse events associated with adjuvant immunotherapy, ultimately enhancing their ability to optimize treatment outcomes and patient care in this setting.=
…
continue reading
Valid until: 29-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/applying-sdm-to-personalize-treatment-discussions-on-recurrence-risk-reduction-in-patients-with-early-stage-melanoma/18105/
This Patient Clinician Connection CME activity, led by Dr. Meghan Mooradian, focuses on the use of adjuvant immunotherapy in early-stage melanoma. The activity aims to educate clinicians on the role of immunotherapy in reducing the risk of disease recurrence post-surgery, particularly in patients with resected stage IIB to III melanoma. Through patient clinical vignettes and audience education vignettes, participants will gain insights into patient-centered approaches, shared decision-making, and the management of immune-related adverse events associated with adjuvant immunotherapy, ultimately enhancing their ability to optimize treatment outcomes and patient care in this setting.=
598 jaksoa
Jaa
